Insider buying last 90 days
No open-market insider purchases were filed for PCRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PCRX insider filing, plotted on the chart in Gekko.Open PCRX in Gekko
NASDAQ: PCRX
Pacira BioSciences (PCRX) Stock Analysis & Forecast
Oct 12 close
$36.35+0.04 (+0.1%)
Gekko Brief
AI summaryOct 12 closePacira BioSciences moves this week on news that Viatris agreed to acquire the company for $1.65 billion in cash, with shareholders set to receive $36.50 per share, expanding Viatris's non-opioid pain portfolio with two marketed pain therapies and a clinical-stage gene therapy candidate. The announced deal has drawn a series of investigation notices from law firms including Kahn Swick & Foti, Monteverde & Associates, Ademi LLP, Brodsky & Smith, and Halper Sadeh, each examining whether the proposed price fairly values Pacira shareholders. Separately, a filing noted that SVP Lauren Riker sold $217,920 in stock on 8 October under a Rule 10b5-1 plan.
PCRX closed at $36.35, little changed on the day, and sits above both its 50-day average of $25.76 and 200-day average of $24.03, with the 50-day above the 200-day. The GekkoIndex reading of 23.9 places the stock in the Selling zone, down 33.5 over five days. Despite the trend positioning, price stands 33.5% below the Gekko Fair Value of $54.68.
Pacira's next earnings date is set for 5 November 2026, after the close, 24 days away and inside a typical 20-trading-day holding window; the prior quarter's report produced a -7.6% reaction despite EPS of $0.73 beating the $0.65 estimate. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged +2.7% across 5 years, rising in 2 of them. Analyst consensus currently reflects 8 hold ratings and 1 sell among 9 firms, with a consensus target of $31.39.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Pacira BioSciences price vs fair value
Close $36.35200-day averageGekko Fair Value $54.68
Pacira BioSciences quick facts
- Market cap
- $1.43B
- P/E ratio
- 104
- Forward P/E
- 6.3
- EPS, TTM
- $0.35
- Revenue, TTM
- $746.2M
- Profit margin
- 2%
- Dividend yield
- —
- Beta
- 0.25
- Volume
- 2.01M avg 2.24M
- 1-year return
- +57.6%
- Typical daily move
- ±4%
- Typical 20-day move
- ±7.4%
- 50-day average
- $25.76
- 200-day average
- $24.03
- Next earnings
- Nov 5 after close
- Shares outstanding
- 39.86M
Pacira BioSciences swing-trade checklist
Pacira BioSciences scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $36.35 is above the 50-day ($25.76) and 200-day ($24.03) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
23.9, Selling
Reading 23.9 is in the Selling zone.
See the GekkoIndex - Fair valuesupportive
33.5% below
Price is 33.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+2.7% on average
From this point in the calendar, the next 20 trading days averaged +2.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Pacira BioSciences stock chart and price history
Pacira BioSciences closed at $36.35 on Oct 12, 2026, +57.6% over the past year, inside a 52-week range of $18.80 to $36.46.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +43.3%
- 3 months
- +45.3%
- 6 months
- +51.1%
- 1 year
- +57.6%
The full PCRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PCRX in Gekko
Follow Pacira BioSciences through every session
Put PCRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PCRX in GekkoFree for 7 days. No credit card required.
About Pacira BioSciences
Pacira BioSciences focuses on non-opioid options for treating pain and supporting regenerative health, serving healthcare providers and the patients they treat in the United States. The company is known for EXPAREL, an injectable suspension of liposomal bupivacaine, along with ZILRETTA, an extended-release injection containing triamcinolone acetonide.
Beyond these two products, Pacira markets the iovera system, a handheld device that uses controlled cold temperatures to target nerves without opioids. The company also builds on its own multivesicular liposome technology, a drug delivery method designed to encapsulate therapeutic compounds while keeping their molecular structure intact.
The company was founded in 2006 and operated under the name Pacira Pharmaceuticals before adopting its current name in April 2019. It is headquartered in Tampa, Florida, and its shares are listed on the NASDAQ under the ticker PCRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- pacira.com
Pacira BioSciences GekkoIndex: the smart money zone
Pacira BioSciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 23.9, in the Selling zone, down 33.5 points over five sessions.
23.9Selling
Down 33.5 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | +1.9% | +3.0% | ||
| Accumulation | 254 | +0.1% | +0.5% | ||
| Neutral | 366 | +0.1% | +0.4% | ||
| Distribution | 22 | +1.3% | −4.2% | ||
| Selling (current zone) | 1 | Too few readings yet | |||
Average PCRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Selling readings averaged +7.4% over 20 days. Past behaviour doesn’t guarantee future results.
Selling zone: Smart money likely exiting positions. About the five zones →
See every daily GekkoIndex reading plotted over the PCRX price, zone by zone.Track PCRX in Gekko
Is Pacira BioSciences stock overvalued? Gekko Fair Value
Pacira BioSciences trades 33.5% below Gekko Fair Value of $54.68, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Pacira BioSciences shares are worth, recalculated every trading day.
$54.68
Gekko Fair Value, Oct 10, 2026
33.5% Undervalued
At the end of Aug 2026 the price was 8.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PCRX in Gekko
Pacira BioSciences insider and Congress trading
No open-market insider purchases were filed for Pacira BioSciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PCRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PCRX, plotted on the chart in Gekko.Open PCRX in Gekko
Buybacks
Pacira BioSciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $50.05M
- As a share of market cap
- 3.50%
- Trailing four quarters
- $198.4M
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold PCRX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Pacira BioSciences earnings: next date and track record
Pacira BioSciences reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.73
- Revenue estimate
- $182.9M
6 of 8reports beat the EPS estimate
±3.6%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Pacira BioSciences reported Q2 2026 revenues exceeding $109 million and adjusted EBITDA of nearly $50 million, executing their 5x30 strategy. EXPAREL gained UnitedHealthcare separate reimbursement coverage, reaching 150 million covered lives. Key pipeline milestones include PCRX-201 manufacturing establishment, Phase 2 ASCENT study enrollment opened, and the completed iovera divestiture with Zimmer Biomet partnership formed for spasticity.
- Guidance
- Full-year covered lives target is 160 million. Top-line data expected from PCRX-201 Part A and ZILRETTA shoulder OA Phase 3 study later this year. PCRX-202 Phase 2 development scheduled to begin later this year.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.73 est $0.65 | $192.4M est $191.1M | −7.6% |
| Apr 30, 2026 | $0.60 est $0.61 | $177.4M est $171.8M | −2.8% |
| Feb 26, 2026 | $0.57 est $0.85 | $196.9M est $200.3M | −6.6% |
| Nov 6, 2025 | $0.70 est $0.65 | $179.5M est $201.9M | +0.9% |
| Aug 5, 2025 | $0.74 est $0.72 | $181.1M est $182.4M | −2.4% |
| May 8, 2025 | $0.62 est $0.57 | $168.9M est $187.5M | −0.2% |
| Feb 27, 2025 | $0.91 est $0.78 | $187.3M est $185.4M | −5.6% |
| Nov 6, 2024 | $0.79 est $0.70 | $168.6M est $179.5M | +2.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Pacira BioSciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Pacira BioSciences is $31.39, −13.6% from the last close, from 9 firms rating the stock in the last 90 days.
$31.39consensus 12-month target, −13.6% from the last close
Now $36.35Avg $31.39
Low $23High $36.50
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 9 | Truist Financial | $36.50 | +0.4% |
| Oct 9 | H.C. Wainwright | $36.50 | +0.4% |
| Oct 9 | Leerink Partners | $36.50 | +0.4% |
| Oct 8 | Jefferies | $36 | −1.0% |
| Oct 8 | Oppenheimer | — | — |
+2.7%average move over the next 20 trading days in the last 5 years
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Pacira BioSciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Pacira BioSciences averaged +2.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 3 of 5 |
| Next 10 trading days | −1.1% | 2 of 5 |
| Next 15 trading days | −1.7% | 2 of 5 |
| Next 20 trading days | +2.7% | 2 of 5 |
| Next 30 trading days | −1.8% | 3 of 5 |
For scale, PCRX’s typical 20-trading-day move in either direction is about 7.4%.
Pacira BioSciences market cap and key statistics
Pacira BioSciences’s market cap is $1.43B, with a P/E ratio of 104 and revenue of $746.2M over the last twelve months.
Valuation
- Market cap
- $1.43B
- P/E ratio
- 104
- Forward P/E
- 6.3
- EPS, TTM
- $0.35
- Gekko Fair Value
- $54.68
Trading
- Volume
- 2.01M
- Avg volume, 20 days
- 2.24M
- 52-week high
- $36.46
- 52-week low
- $18.80
- Shares outstanding
- 39.86M
Financials
- Revenue, TTM
- $746.2M
- Profit margin
- 2%
- Return on equity
- 2.1%
- Quarterly earnings growth, YoY
- −30.0%
Risk and income
- Beta
- 0.25
- Typical daily move
- ±4%
- Typical 20-day move
- ±7.4%
Pacira BioSciences stock news this week
Coverage of Pacira BioSciences this week reads positive: 9 positive, 2 neutral and 2 negative headlines.
- Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRXBusiness Wire, Oct 12
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PR Newswire, Oct 11
- Pacira BioSciences SVP Lauren Riker sells $217,920 in stockInvesting.com, Oct 11
- After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares.Stock Titan, Oct 9
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research, Oct 9
- PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.Morningstar, Oct 9
Pacira BioSciences peers
Pacira BioSciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Pacira BioSciences stock FAQ
What is Pacira BioSciences’s market cap?
Pacira BioSciences’s market cap is $1.43B at the Oct 12, 2026 close of $36.35, with 39.86M shares outstanding. The shares trade on a P/E ratio of 104.
What is the Pacira BioSciences stock forecast?
The consensus analyst 12-month price target for Pacira BioSciences is $31.39, −13.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 0 rate it a buy, 8 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Pacira BioSciences stock overvalued or undervalued?
On Gekko’s estimate Pacira BioSciences is undervalued: the Oct 12, 2026 close of $36.35 is 33.5% below Gekko Fair Value of $54.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Pacira BioSciences report earnings next?
Pacira BioSciences is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.73 per share on revenue of $182.9M. Pacira BioSciences beat the earnings estimate in 6 of its last 8 reports, moving 3.6% on average across the report.
What is Pacira BioSciences’s 52-week high and low?
Pacira BioSciences’s 52-week high is $36.46 and its 52-week low is $18.80; it closed at $36.35 on Oct 12, 2026, +57.6% over the past year. Over the last five years the shares peaked at $82.16 on Apr 8, 2022.
Is Pacira BioSciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (seasonality) and 2 as headwinds (gekkoindex and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Pacira BioSciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.